214 related articles for article (PubMed ID: 7577621)
21. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
22. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
Diccianni MB; Chau LS; Batova A; Vu TQ; Yu AL
Cancer Lett; 1996 Jul; 104(2):183-92. PubMed ID: 8665486
[TBL] [Abstract][Full Text] [Related]
23. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
24. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
Southgate J; Proffitt J; Roberts P; Smith B; Selby P
Br J Cancer; 1995 Nov; 72(5):1214-8. PubMed ID: 7577470
[TBL] [Abstract][Full Text] [Related]
25. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines.
Akama Y; Yasui W; Kuniyasu H; Yokozaki H; Akagi M; Tahara H; Ishikawa T; Tahara E
Jpn J Cancer Res; 1996 Aug; 87(8):824-30. PubMed ID: 8797888
[TBL] [Abstract][Full Text] [Related]
26. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Zariwala M; Liu E; Xiong Y
Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
[TBL] [Abstract][Full Text] [Related]
27. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
28. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Zariwala M; Xiong Y
Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
[TBL] [Abstract][Full Text] [Related]
29. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).
Yuan C; Li J; Selby TL; Byeon IJ; Tsai MD
J Mol Biol; 1999 Nov; 294(1):201-11. PubMed ID: 10556039
[TBL] [Abstract][Full Text] [Related]
30. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
31. Alterations of p16 and p15 genes in acute leukemia with MLL gene rearrangements and their correlation with clinical features.
Ohnishi H; Guo SX; Ida K; Taki T; Naritaka S; Bessho F; Yanagisawa M; Hanada R; Eguchi M; Kamada N; Kita K; Yamamori S; Hayashi Y
Leukemia; 1997 Dec; 11(12):2120-4. PubMed ID: 9447829
[TBL] [Abstract][Full Text] [Related]
32. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
Kulkarni MS; Daggett JL; Bender TP; Kuehl WM; Bergsagel PL; Williams ME
Leukemia; 2002 Jan; 16(1):127-34. PubMed ID: 11840272
[TBL] [Abstract][Full Text] [Related]
33. The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster.
Aguiar RC; Sill H; Goldman JM; Cross NC
Leukemia; 1997 Feb; 11(2):233-8. PubMed ID: 9009086
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias.
Chim CS; Wong AS; Kwong YL
Ann Hematol; 2003 Dec; 82(12):738-42. PubMed ID: 14513284
[TBL] [Abstract][Full Text] [Related]
35. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.
Omura-Minamisawa M; Diccianni MB; Batova A; Chang RC; Bridgeman LJ; Yu J; Pullen J; Bowman WP; Yu AL
Clin Cancer Res; 2000 Apr; 6(4):1219-28. PubMed ID: 10778944
[TBL] [Abstract][Full Text] [Related]
36. Absence of p18 mutations or deletions in lymphoid malignancies.
Otsuki T; Jaffe ES; Wellmann A; Kumar S; Condron KS; Raffeld M
Leukemia; 1996 Feb; 10(2):356-60. PubMed ID: 8637248
[TBL] [Abstract][Full Text] [Related]
37. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
[TBL] [Abstract][Full Text] [Related]
38. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level.
Jamal R; Thomas NS; Gale RE; Linch DC
Leukemia; 1996 Apr; 10(4):629-36. PubMed ID: 8618439
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas.
Kawamata N; Seriu T; Koeffler HP; Bartram CR
Cancer; 1996 Feb; 77(3):570-5. PubMed ID: 8630967
[TBL] [Abstract][Full Text] [Related]
40. Frequent hypermethylation of p16 and p15 genes in multiple myeloma.
Ng MH; Chung YF; Lo KW; Wickham NW; Lee JC; Huang DP
Blood; 1997 Apr; 89(7):2500-6. PubMed ID: 9116295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]